How to Value a Pharmacy in Australia

What is actually being valued

Before a figure is produced, the subject and the basis have to be settled. Most pharmacy valuations are of the business as a going concern: the right to trade from approved premises, the lease, the fitout and dispensary plant, the trading systems and the goodwill attached to the location. Goodwill is the value of the business over and above its identifiable net assets, being the assets less the liabilities.

Most engagements use a market value basis: what a willing but not anxious buyer and seller, each properly informed and dealing at arm's length, would agree. Market value is not price. Price is what one party actually paid, and it may carry a premium for a benefit only that buyer enjoys, or a discount because the vendor had to settle quickly.

Where the pharmacy is held through a pharmacist company, partnership or unit trust, the subject may be shares, partnership interests or units rather than the business. The valuation first reaches enterprise value, the value of the operating business before borrowings, then deducts interest-bearing debt, adds surplus assets and adjusts working capital (the funds tied up in stock and debtors less trade creditors) to the level the business needs, giving equity value. A parcel without control may then attract a minority discount, and a controlling parcel a control premium, because a small holder cannot set drawings, appoint the pharmacist in charge or compel a sale. Whether either applies depends on the purpose and on any shareholders or partnership agreement. See share and equity valuations.

The valuation date, the date as at which value is assessed, is not a formality. A pharmacy valued the month before a competitor opens across the road is a different business from the same pharmacy a month later.

Why the approval and the address come first

A community pharmacy earns most of its income because it is approved to supply pharmaceutical benefits. Approval is granted under section 90 of the National Health Act 1953 to supply from particular premises, a unique PBS pharmacy approval number is issued for each approved premises, and an approved pharmacist may only supply pharmaceutical benefits at or from the premises for which they have been approved.

The approval therefore does not travel with the contract of sale: the incoming pharmacist applies for their own approval at that address, and the business is tied to a street address as a medical or allied health practice is not.

Where a pharmacy can be, and where a competitor can be, is governed by the Pharmacy Location Rules, made as a legislative instrument, the National Health (Australian Community Pharmacy Authority Rules) Determination 2018, in force at the time of writing. They set out when the Australian Community Pharmacy Authority must, and must not, recommend that an applicant be approved to supply at particular premises. That shelters an established pharmacy from a new approval opening beside it, the main reason pharmacy goodwill is transferable rather than personal, and it means a pharmacy that loses its premises cannot simply reopen down the street.

Transferable goodwill, sometimes called commercial goodwill, passes to a buyer with the business. Personal goodwill depends on an individual and leaves when they do. Pharmacy sits nearer the transferable end than a medical practice, where patients tend to follow the doctor. Some personal element usually remains where the owner is the pharmacist in charge and known to local prescribers, priced as key-person risk, the risk that earnings depend on one individual. Carrying it across turns on a handover and a restraint the seller can be held to.

Reading the script file

Script volume is the nearest thing a pharmacy has to a recurring revenue base, so the dispensing data is analysed before the profit and loss is relied on: monthly script counts across several financial years, split between PBS, private and over the counter supply, between general and concessional patients, and between standard and increased quantity supply.

Mix says more than the total. A high share of chronic repeat medicines indicates a patient base that returns on a predictable cycle; a high share of acute scripts indicates a business exposed to whoever is prescribing nearby. Where many scripts come from one co-located medical practice, a single prescriber retiring can move the earnings, which is concentration risk rather than a growth story. See patient, participant and referral concentration.

Supply arrangements with residential aged care homes deserve their own line: predictable volume, but usually resting on a contract or understanding the operator can end.

How dispensing income is earned

Dispensing remuneration is set by the Commonwealth. At the time of writing it sits under the eighth Community Pharmacy Agreement, which commenced on 1 July 2024 for a five year term and introduced the Additional Community Supply Support payment. The fees are published by the Pharmaceutical Benefits Scheme and they change.

On the PBS fee schedule current at 1 July 2026, a ready-prepared PBS supply attracts a dispensing fee of $9.24 and a Tier One administration, handling and infrastructure fee of $5.12, alongside the price of the medicine. Tier One applies to brands priced to pharmacists under $100 for the maximum quantity and the higher tiers pay more on dearer brands, so a dispensary weighted to high-cost medicines earns a different fee profile from one weighted to generics. The Additional Community Supply Support payment is $5.12 per dispense on supply with increased dispensing quantities, and $0.13 per dispense on each supply.

Patient contributions matter for a separate reason. On the same schedule the general contribution is $25.00, reduced from $31.60 with effect from 1 January 2026, and the concessional contribution is $7.70. Where a medicine's dispensed price sits below the general contribution, the Commonwealth pays nothing and the patient pays the pharmacy's own price, so a lower contribution moves some of those medicines back inside the subsidised system and changes the fees earned on them.

The point is not the arithmetic, it is the exposure. A material part of a pharmacy's gross profit is priced by an agreement with an expiry and by determinations the owner does not influence. That is structural risk, and it belongs in the rate applied to earnings rather than set aside because recent years looked steady. See government funding exposure.

What increased quantity prescriptions changed

A defined list of PBS medicines is available on 60-day prescriptions, published with their item codes on the PBS website, so an eligible patient can receive two months of medicine in a single supply.

The effect is mechanical: one dispensing event replaces two, so dispensing and handling fee income falls for those patients even though the quantity of medicine does not. The Additional Community Supply Support payment offsets part of the shortfall and dispensary time is released. How much this matters differs from pharmacy to pharmacy, so it is measured from the pharmacy's own script counts and dispensary gross profit before and after, and from whether the released hours went into services that earn separately.

Front of shop, margin and stock

A pharmacy's gross margin blends a regulated dispensary margin with an unregulated retail margin on over the counter medicines, vitamins, skincare and general merchandise. A discount format trades margin for volume; a strip pharmacy beside a busy practice often does the reverse. Wholesaler trading terms, banner group fees and rebates move the blend again, so margin is analysed by category rather than as one figure over turnover.

Supply and banner agreements are read rather than summarised. They may run for a fixed term, require minimum purchasing, tie the pharmacy to a shopfront format, carry rebates recognised unevenly, or need consent to assign. Terms a buyer cannot inherit are not part of maintainable earnings.

Stock is usually the largest component of working capital, and in many pharmacy sales it is counted near settlement and paid for at cost on top of the agreed price, so a valuation states plainly whether stock sits inside or outside the concluded figure. Dated, slow-moving and non-returnable lines inflate both reported inventory and the working capital a buyer must fund.

Professional services as a second earnings stream

Approved pharmacies also earn from Commonwealth-funded medication management and adherence programs administered by the Pharmacy Programs Administrator, alongside vaccination and other clinical services. That income is capped and conditional: on the Administrator's terms a MedsCheck attracts $66.53 and a Diabetes MedsCheck $99.79, no more than twenty of these services in total may be claimed per service provider per calendar month, and the patient cannot be charged a gap.

Income of that shape needs a trained pharmacist, a private consultation area and time out of the dispensary, so it is tested against capacity rather than extrapolated. A pharmacy at a program cap has no headroom in it; one with rooms, immunisers and spare staff hours has capacity a buyer could use, which is a growth argument, not a maintainable earnings argument.

Normalising the owner pharmacist out of the accounts

Normalisation means adjusting reported results to show what the business earns independently of its current owner and of one-off events. Maintainable earnings are what remains: the profit the business can reasonably be expected to sustain. See what is maintainable earnings.

In a pharmacy the largest adjustment is almost always the owner. An owner who works as pharmacist in charge and takes drawings rather than a wage has removed a real cost from the accounts. A market salary for the hours actually worked in the dispensary goes back in, with on-costs such as superannuation and leave cover, and with the locum or second pharmacist the roster requires. Family members on the payroll are tested the same way.

The other recurring adjustments are related-party rent restated to market, non-recurring items such as fitout and relocation application costs, legal fees and insurance recoveries, the timing of program payments so income sits in the period the supplies were made, and stocktake irregularities that distort gross margin.

The premises, the plant and the lease

Because the approval attaches to the premises, the lease is not an administrative detail. The remaining term, the options, the rent review mechanism, any turnover rent, any make good obligation and any demolition or relocation clause feed into the valuation twice: once through the maintainable rent in the earnings, and once through the risk attached to them.

The plant sits inside the same shop and largely cannot be moved: the dispensary fitout, any dispensing robot or automated storage, dose administration aid packing equipment, cold chain refrigeration and monitoring, the Schedule 8 safe, the consultation and vaccination room and the dispensing software. Each is assessed for condition and remaining life, and recent capital spending is separated into maintenance and expansion, because a deferred fitout is a cost a buyer will meet.

Premises and lease security therefore sit close to the centre of a pharmacy valuation. See premises and lease terms.

Who is legally allowed to buy

Ownership law sets the buyer pool, which is part of what market value means. In New South Wales only a registered pharmacist may hold a financial interest in a pharmacy, with limited exceptions, and no pharmacist may have an interest in more than five pharmacies in that state. In Queensland the Pharmacy Business Ownership Act 2024 requires a pharmacy business licence, defines who is an eligible person, and caps an eligible person at five pharmacy businesses, or six for qualifying friendly societies. Other states and territories set their own rules and limits and the position may change, so it is confirmed with the relevant regulator at the valuation date and the licensing status of the business is a due diligence item.

A pharmacist or group already at a cap is not a purchaser unless they sell something first, which thins the market for larger pharmacies, and capital from outside the profession cannot take a direct interest, so a structure a compliant buyer can step into is worth more than one that has to be unpicked. Where a group is restructured to stay inside a cap, the transfer values may also matter for tax and duty, which should be confirmed with your accountant or lawyer. See tax and restructure valuations.

From earnings to a value, and the cross-checks

The primary method for an established pharmacy is capitalisation of future maintainable earnings. Normalised maintainable earnings, usually expressed as EBITDA (earnings before interest, tax, depreciation and amortisation) or EBIT (earnings before interest and tax), are capitalised at a rate reflecting the return a buyer requires for earnings of that risk and the growth expected in them; the multiple commonly quoted is its reciprocal. Lease security, script growth and mix, margin balance, workforce dependence, services capacity and policy exposure all move it. Because EBITDA and EBIT are measured before interest, capitalising them gives the value of the business before borrowings; debt, surplus assets and working capital are handled after that step, not inside it. See EBITDA multiples for healthcare businesses. A rule of thumb applied to a particular pharmacy is not a valuation, and a multiple applied to earnings that were never normalised is worse than none.

Discounted cash flow discounts forecast cash flows, and a terminal value, back to the valuation date at a rate reflecting their risk and the time value of money. It suits situations where the past will not repeat: a recent relocation, a new approval, or a change in remuneration not yet absorbed. It is only as good as the forecast, so the assumptions are stated rather than buried.

A net assets basis values the identifiable assets, restated from book to market value, less the liabilities. It is used where earnings do not support goodwill, and otherwise as a check on the going concern conclusion against the fitout, dispensary automation and stock on the floor. Market evidence from pharmacy sales tests that conclusion but has to be adjusted first, because reported prices commonly exclude stock, treat plant differently, reflect a lease and location unlike the subject, or involve a buyer who was not at arm's length.

Purpose shapes all of this. A valuation for a sale, a shareholder exit, a tax or restructure event, a family law matter or a dispute may use a different basis, date and scope, so a report prepared for one purpose does not automatically suit another. Pharmacy lending and broking are specialised fields of their own, so an owner may be shown more than one figure: a financier can commission a valuation directed at the security behind a loan rather than at market value, and a broker appraisal estimates a likely sale outcome. See how it works, preparing a healthcare business for sale and business valuation versus business appraisal.

What actually changes the number

Value rises with what makes earnings durable and transferable: a secure lease at a protected location, steady script growth over a base of chronic repeat medicines, a front of shop that earns its floor space, services capacity actually available, employed pharmacists and documented systems, supply terms a buyer can inherit and clean stock control.

Value falls with the mirror images: a lease running down, dependence on one prescriber or one aged care facility, margin propped up by discounting, an owner working unpaid hours a buyer will have to fund, a stock file nobody has counted properly, and a structure few compliant buyers can step into. None of that is fixed by choosing a higher multiple. It is fixed, if at all, in the business.

For an independent conclusion for a stated purpose, request a valuation or read more about pharmacy valuations.